- MoonLake Immunotherapeutics stock up 13% on positive data for skin condition treatment
- Phase 2 Mira trial shows further improvements in patients with moderate-to-severe hidradenitis suppurativa
- MoonLake on track to discuss phase 3 development plans with FDA by end of the year
Shares of MoonLake Immunotherapeutics climbed 13% after the company announced positive 24-week results from a trial for treating a chronic inflammatory skin condition. The phase 2 Mira trial demonstrated that maintenance treatment with MoonLake’s sonelokimab led to additional improvements in patients with moderate-to-severe hidradenitis suppurativa. MoonLake’s CEO, Jorge Santos da Silva, stated that the company is on schedule to discuss its phase 3 development plans with the FDA before the year ends.
